Abstract
Patients who undergo drug-eluting coronary stent (DES) implantation require dual antiplatelet therapy for at least 6 months. When these patients require non-cardiac surgery, determination of the most appropriate antiplatelet therapy to minimize the risk of stent thrombosis and/or bleeding complications is always difficult. In particular, patients who have just undergone DES implantation have an extremely high risk of stent thrombosis, and delaying surgery is required to reduce the risk. We herein report the case of a male patient in whom hilar cholangiocarcinoma was detected just after implanting DES and who safely underwent curative resection for the hilar cholangiocarcinoma following neoadjuvant chemotherapy. This case serves as an example of successful resolution of this challenging problem.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have